Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the cost and importance of developing MDMA into medicine, and how his organization is working towards FDA approval. Despite the high costs and extensive studies required, Doblin is passionate about the potential benefits of MDMA therapy for those affected by trauma and addiction.